RICHMOND, Va., Nov. 7, 2024
/PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) the Board of
Directors (the "Board") of Indivior plc ("Indivior" or the
"Company") notes the publication today of a letter from Oaktree
Capital Management LP ("Oaktree") to the Board of Indivior.
The Board has engaged actively with Oaktree in recent weeks on
these topics, and remains open-minded about all proposals to
enhance value creation. The Board is focused on acting in the best
interests of all shareholders as we continue to execute on our
strategy.
Indivior looks forward to further engagement with Oaktree
and other shareholders.
About Indivior
Indivior is a global pharmaceutical company working to help
change patients' lives by developing medicines to treat substance
use disorders (SUD). Our vision is that all patients around the
world will have access to evidence-based treatment for the chronic
conditions and co-occurring disorders of SUD. Indivior is dedicated
to transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to expand on its heritage in this category. Headquartered in
the United States in Richmond, VA, Indivior employs over 1,000
individuals globally and its portfolio of products is available in
over 30 countries worldwide. Visit www.indivior.com to learn more.
Connect with Indivior on LinkedIn by visiting
www.linkedin.com/company/indivior.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/indivior-responds-to-publication-of-a-letter-by-oaktree-capital-management-to-the-board-of-indivior-302299220.html
SOURCE Indivior PLC